Augmenix tissue-marking product for surgeries gets FDA clearance


Augmenix Inc., a Waltham company focused on the development and commercialization of radiation oncology products using its proprietary hydrogel technology, said Monday that it has received clearance from the US Food and Drug Administration to market an absorbable tissue marker visible that helps medical personnel to plan surgical procedures.

The product is called TraceIT Tissue Marker, and it is designed to “radiographically mark soft tissue during a surgical procedure or for future surgical procedures,” Augmenix said in a press release.

Augmenix describes TraceIT Tissue Marker as a synthetic hydrogel consisting primarily of water and iodinated cross-linked polyethylene glycol.Small hydrogel injections are clearly visible in the lung, breast, prostate, and other tissues, the release said.

Chris Reidy can be reached at
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of